2024
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
Ascierto P, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, Cossu A, Mandalà M, Ferrucci P, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Fierro M, Lebbe C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Cao M, Minisini A, De Placido S, Sanmamed M, Mallardo D, Paone M, Vitale M, Melero I, Grimaldi A, Giannarelli D, Dummer R, Sileni V, Palmieri G. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nature Communications 2024, 15: 146. PMID: 38167503, PMCID: PMC10761671, DOI: 10.1038/s41467-023-44475-6.Peer-Reviewed Original ResearchConceptsOverall survivalSurvival outcomesNoncomparative phase II trialTotal progression-free survivalLong-term survival outcomesMEK inhibitionBRAF/MEK inhibitionFirst-line treatment approachFirst-line treatment optionBRAF/MEK inhibitorsT-lymphocyte antigen-4Cell death protein 1BRAFV600-mutant melanomaDual checkpoint blockadeFirst-line immunotherapyMetastatic BRAF V600Serum interferon gammaPhase II trialProgression-free survivalDeath protein 1BRAFV600-mutant metastatic melanomaLow baseline levelsBiomarker analysisCombination BRAFSequential immunotherapy
2020
Comparative efficacy of chemoimmunotherapy versus immunotherapy alone in the front-line treatment of advanced non-small cell lung cancer: A systematic review and network meta-analysis.
Pathak R, Lopes G, Yu H, Ji W, Aryal M, Frumento K, Wallis C, Klaassen Z, Park H, Goldberg S. Comparative efficacy of chemoimmunotherapy versus immunotherapy alone in the front-line treatment of advanced non-small cell lung cancer: A systematic review and network meta-analysis. Journal Of Clinical Oncology 2020, 38: 9552-9552. DOI: 10.1200/jco.2020.38.15_suppl.9552.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsIpi/nivoPD-1 axis inhibitorsPD-L1 1Phase 3 RCTsPD-L1 statusPD-L1Advanced non-small cell lung cancerSingle-agent immune checkpoint inhibitorsSystematic reviewCombination immune checkpoint inhibitorsNon-small cell lung cancerDual checkpoint blockadeCTLA-4 inhibitorsFront-line treatmentCell lung cancerSignificant differencesAdvanced NSCLCICI monotherapyOS benefitCheckpoint inhibitorsProspective trialCheckpoint blockadeCombination chemotherapyNSCLC patients
2018
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
Hung A, Maxwell R, Theodros D, Belcaid Z, Mathios D, Luksik A, Kim E, Wu A, Xia Y, Garzon-Muvdi T, Jackson C, Ye X, Tyler B, Selby M, Korman A, Barnhart B, Park S, Youn J, Chowdhury T, Park C, Brem H, Pardoll D, Lim M. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. OncoImmunology 2018, 7: e1466769. PMID: 30221069, PMCID: PMC6136875, DOI: 10.1080/2162402x.2018.1466769.Peer-Reviewed Original ResearchTumor-infiltrating dendritic cellsCervical lymph nodesTIGIT expressionT cellsTherapeutic targetEffector T cell functionDual checkpoint blockadePatient GBM samplesUnderlying immune mechanismsRegulatory T cellsTumor-infiltrating lymphocytesPoor survival outcomesNovel checkpoint inhibitorsT cell functionManagement of glioblastomaEffective treatment strategiesImmune therapeutic targetsLow-grade gliomasHuman GBM cellsMurine glioblastoma modelValuable therapeutic targetSuppressive TregsTIGIT pathwayCheckpoint inhibitorsInhibitory checkpoints
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply